Effects of 5-Hydroxytryptamine Class 2 Receptor Antagonists on Bronchoconstriction and Pulmonary Remodeling Processes
(2018) In American Journal of Pathology 188(5). p.1113-1119- Abstract
Serotonin [5-hydroxytryptamine (5-HT)] is associated with several chronic pulmonary diseases, recognizing 5-HT2 receptor antagonists as potential inhibitors of tissue remodeling. However, the effects of 5-HT2 receptors, especially 5-HT2B receptors on airway function and remodeling, are unclear. We investigated the role of 5-HT2B receptors on airway smooth muscle contractility and remodeling processes. Murine precision-cut lung slices were pretreated with 5-HT2B receptor antagonists (EXT5, EXT9, RS 127445, and PRX 08066), as well as ketanserin (5-HT2A/2C receptor antagonist) (1, 10 μmol/L), before addition of cumulative concentrations of 5-HT to induce bronchoconstriction.... (More)
Serotonin [5-hydroxytryptamine (5-HT)] is associated with several chronic pulmonary diseases, recognizing 5-HT2 receptor antagonists as potential inhibitors of tissue remodeling. However, the effects of 5-HT2 receptors, especially 5-HT2B receptors on airway function and remodeling, are unclear. We investigated the role of 5-HT2B receptors on airway smooth muscle contractility and remodeling processes. Murine precision-cut lung slices were pretreated with 5-HT2B receptor antagonists (EXT5, EXT9, RS 127445, and PRX 08066), as well as ketanserin (5-HT2A/2C receptor antagonist) (1, 10 μmol/L), before addition of cumulative concentrations of 5-HT to induce bronchoconstriction. Remodeling effects after treatment with 10 μmol/L 5-HT and 5-HT2 receptor antagonists were further studied in distal lung tissue by examining release of profibrotic transforming growth factor (TGF)-β1 and proliferation of human bronchial smooth muscle cells (HBSMCs). 5-HT–induced bronchoconstriction was significantly reduced by EXT5, EXT9, and ketanserin, but not by RS 127445 or PRX 08066. The 5-HT2B receptor antagonists significantly reduced TGF-β1 release. 5-HT, in combination with TGF-β1, increased proliferation of HBSMCs, a process reduced by EXT5 and EXT9. Our results indicate that EXT5 and EXT9 may relieve bronchoconstriction in murine airways and serve as an add-on effect in attenuating pulmonary remodeling by improving airway function. The antiproliferative effect on HBSMCs and the inhibition of TGF-β1 release further support a role of 5-HT2B receptors in pathologic remodeling processes.
(Less)
- author
- Löfdahl, Anna LU ; Wenglén, Christina LU ; Rydell-Törmänen, Kristina LU ; Westergren-Thorsson, Gunilla LU and Larsson-Callerfelt, Anna Karin LU
- organization
- publishing date
- 2018-05-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- American Journal of Pathology
- volume
- 188
- issue
- 5
- pages
- 7 pages
- publisher
- American Society for Investigative Pathology
- external identifiers
-
- pmid:29454752
- scopus:85045031213
- ISSN
- 0002-9440
- DOI
- 10.1016/j.ajpath.2018.01.006
- language
- English
- LU publication?
- yes
- id
- c42f3470-5199-4383-9bc4-6f93fac4446e
- date added to LUP
- 2018-04-17 13:44:39
- date last changed
- 2024-10-15 01:08:27
@article{c42f3470-5199-4383-9bc4-6f93fac4446e, abstract = {{<p>Serotonin [5-hydroxytryptamine (5-HT)] is associated with several chronic pulmonary diseases, recognizing 5-HT<sub>2</sub> receptor antagonists as potential inhibitors of tissue remodeling. However, the effects of 5-HT<sub>2</sub> receptors, especially 5-HT<sub>2B</sub> receptors on airway function and remodeling, are unclear. We investigated the role of 5-HT<sub>2B</sub> receptors on airway smooth muscle contractility and remodeling processes. Murine precision-cut lung slices were pretreated with 5-HT<sub>2B</sub> receptor antagonists (EXT5, EXT9, RS 127445, and PRX 08066), as well as ketanserin (5-HT<sub>2A/2C</sub> receptor antagonist) (1, 10 μmol/L), before addition of cumulative concentrations of 5-HT to induce bronchoconstriction. Remodeling effects after treatment with 10 μmol/L 5-HT and 5-HT<sub>2</sub> receptor antagonists were further studied in distal lung tissue by examining release of profibrotic transforming growth factor (TGF)-β1 and proliferation of human bronchial smooth muscle cells (HBSMCs). 5-HT–induced bronchoconstriction was significantly reduced by EXT5, EXT9, and ketanserin, but not by RS 127445 or PRX 08066. The 5-HT<sub>2B</sub> receptor antagonists significantly reduced TGF-β1 release. 5-HT, in combination with TGF-β1, increased proliferation of HBSMCs, a process reduced by EXT5 and EXT9. Our results indicate that EXT5 and EXT9 may relieve bronchoconstriction in murine airways and serve as an add-on effect in attenuating pulmonary remodeling by improving airway function. The antiproliferative effect on HBSMCs and the inhibition of TGF-β1 release further support a role of 5-HT<sub>2B</sub> receptors in pathologic remodeling processes.</p>}}, author = {{Löfdahl, Anna and Wenglén, Christina and Rydell-Törmänen, Kristina and Westergren-Thorsson, Gunilla and Larsson-Callerfelt, Anna Karin}}, issn = {{0002-9440}}, language = {{eng}}, month = {{05}}, number = {{5}}, pages = {{1113--1119}}, publisher = {{American Society for Investigative Pathology}}, series = {{American Journal of Pathology}}, title = {{Effects of 5-Hydroxytryptamine Class 2 Receptor Antagonists on Bronchoconstriction and Pulmonary Remodeling Processes}}, url = {{http://dx.doi.org/10.1016/j.ajpath.2018.01.006}}, doi = {{10.1016/j.ajpath.2018.01.006}}, volume = {{188}}, year = {{2018}}, }